Tygacil and Cymbalta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tygacil and Cymbalta. Common interactions include vomiting among females and blood alkaline phosphatase increased among males.

The phase IV clinical study analyzes what interactions people who take Tygacil and Cymbalta have. It is created by eHealthMe based on reports of 13 people who take Tygacil and Cymbalta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

13 people who take Tygacil and Cymbalta together, and have interactions are studied.


What is Tygacil?

Tygacil has active ingredients of tigecycline. eHealthMe is studying from 1,956 Tygacil users for its effectiveness, alternative drugs and more.

What is Cymbalta?

Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 145,318 Cymbalta users for its effectiveness, alternative drugs and more.

Number of Tygacil and Cymbalta reports submitted per year:

Tygacil and Cymbalta drug interactions.

Common Tygacil and Cymbalta drug interactions by gender *:

female:

  1. Vomiting
  2. Gastrointestinal haemorrhage
  3. Nausea
  4. Cardio-respiratory arrest
  5. Coagulopathy
  6. Gastrointestinal stoma complication
  7. Hypotension
  8. Kidney infection
  9. Multi-organ failure
  10. Peritoneal disorder

male:

  1. Blood alkaline phosphatase increased
  2. Gamma-glutamyltransferase increased
  3. Convulsion
  4. Culture urine positive
  5. Deep vein thrombosis
  6. Dementia
  7. Enterococcus test positive
  8. Escherichia test positive
  9. General physical health deterioration
  10. Hypertension

Common Tygacil and Cymbalta drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Vomiting
  2. Nausea

40-49:

  1. Cardio-respiratory arrest
  2. Gastrointestinal stoma complication
  3. Hypotension
  4. Multi-organ failure
  5. Peritoneal disorder
  6. Peritonitis
  7. Pyrexia
  8. Sepsis

50-59:

  1. Activated partial thromboplastin time prolonged
  2. Alanine aminotransferase increased
  3. Aspartate aminotransferase increased
  4. Blood alkaline phosphatase increased
  5. Gamma-glutamyltransferase increased
  6. Cellulitis
  7. Oedema

60+:

  1. Gastrointestinal haemorrhage
  2. Blood alkaline phosphatase increased
  3. Culture urine positive
  4. Deep vein thrombosis
  5. Dementia
  6. Enterococcus test positive
  7. Escherichia test positive
  8. General physical health deterioration
  9. Hypertension
  10. Hyponatraemia

Common conditions people have *:

  1. Pain: 2 people, 15.38%
  2. Lyme Disease (a bacterial infection that is spread to humans by infected ticks): 2 people, 15.38%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 15.38%
  4. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 7.69%
  5. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 7.69%
  6. Osteomyelitis Chronic (long lasting infection of bone marrow): 1 person, 7.69%
  7. Infection: 1 person, 7.69%
  8. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 7.69%
  9. High Blood Pressure: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Tygacil and Cymbalta?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Tygacil and Cymbalta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tygacil side effects:

Browse all side effects of Tygacil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cymbalta side effects:

Browse all side effects of Cymbalta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tygacil interactions:

Browse all interactions between Tygacil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cymbalta interactions:

Browse all interactions between Cymbalta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tigecycline and duloxetine hydrochloride (the active ingredients of Tygacil and Cymbalta, respectively), and Tygacil and Cymbalta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Tygacil and Cymbalta.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: